Literature DB >> 3341399

Progesterone profiles in luteal phase defect cycles and outcome of progesterone treatment in patients with recurrent spontaneous abortion.

S Daya1, S Ward, E Burrows.   

Abstract

The existence of luteal phase defect has been the focus of much debate, mainly because of inconsistencies in its diagnosis and management. This study was performed to compare progesterone profiles in women with luteal phase defect with those of women with normal cycles and to establish a discriminatory level of serum progesterone that may aid in the diagnosis of this condition. Compared with patients with luteal phase defect cycles, women with normal cycles produced significantly more progesterone in the luteal phase. The serum progesterone level (less than or equal to 21 nmol/L) was the optimal discriminatory level between luteal phase defect and normal cycles and provided a diagnostic test with 70% sensitivity and 71% specificity. In women with recurrent abortion, the incidence of luteal phase defect was 40%, but with treatment 81% of pregnancies were successful. The findings in this study support the existence of luteal phase defect as a clinically significant entity in recurrent first-trimester spontaneous abortion and one that can be treated successfully with the administration of progesterone. The histologic diagnosis of luteal phase defect may also be confirmed with serum progesterone.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3341399     DOI: 10.1016/0002-9378(88)90127-5

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  9 in total

1.  Investigation of the infertile couple.

Authors:  S Daya
Journal:  Can Fam Physician       Date:  1989-06       Impact factor: 3.275

2.  Progesterone profiles in luteal-phase defects associated with recurrent spontaneous abortions.

Authors:  R Babalioğlu; F G Varol; R Ilhan; O Yalçin; F Cizmecioğlu
Journal:  J Assist Reprod Genet       Date:  1996-04       Impact factor: 3.412

3.  A Case Report on A Myomectomy which was Done During A Caesarean Section.

Authors:  Ratnamal M Desai
Journal:  J Clin Diagn Res       Date:  2013-03-07

4.  Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology.

Authors:  David M Haas; Taylor J Hathaway; Patrick S Ramsey
Journal:  Cochrane Database Syst Rev       Date:  2019-11-20

5.  Progestogens for preventing miscarriage: a network meta-analysis.

Authors:  Adam J Devall; Argyro Papadopoulou; Marcelina Podesek; David M Haas; Malcolm J Price; Arri Coomarasamy; Ioannis D Gallos
Journal:  Cochrane Database Syst Rev       Date:  2021-04-19

6.  Trafficking of cholesterol from lipid droplets to mitochondria in bovine luteal cells: Acute control of progesterone synthesis.

Authors:  Michele R Plewes; Crystal Krause; Heather A Talbott; Emilia Przygrodzka; Jennifer R Wood; Andrea S Cupp; John S Davis
Journal:  FASEB J       Date:  2020-07-02       Impact factor: 5.834

Review 7.  Micronized vaginal progesterone to prevent miscarriage: a critical evaluation of randomized evidence.

Authors:  Arri Coomarasamy; Adam J Devall; Jan J Brosens; Siobhan Quenby; Mary D Stephenson; Sony Sierra; Ole B Christiansen; Rachel Small; Jane Brewin; Tracy E Roberts; Rima Dhillon-Smith; Hoda Harb; Hannah Noordali; Argyro Papadopoulou; Abey Eapen; Matt Prior; Gian Carlo Di Renzo; Kim Hinshaw; Ben W Mol; Mary Ann Lumsden; Yacoub Khalaf; Andrew Shennan; Mariette Goddijn; Madelon van Wely; Maya Al-Memar; Phil Bennett; Tom Bourne; Raj Rai; Lesley Regan; Ioannis D Gallos
Journal:  Am J Obstet Gynecol       Date:  2020-01-31       Impact factor: 8.661

8.  Progesterone supplementation in women with otherwise unexplained recurrent miscarriages.

Authors:  Munawar Hussain; Samawal El-Hakim; David J Cahill
Journal:  J Hum Reprod Sci       Date:  2012-09

9.  Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology.

Authors:  David M Haas; Taylor J Hathaway; Patrick S Ramsey
Journal:  Cochrane Database Syst Rev       Date:  2018-10-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.